作者
Daniel E Spratt, Jingbin Zhang, María Santiago-Jiménez, Robert T Dess, John W Davis, Robert B Den, Adam P Dicker, Christopher J Kane, Alan Pollack, Radka Stoyanova, Firas Abdollah, Ashley E Ross, Adam Cole, Edward Uchio, Josh M Randall, Hao Nguyen, Shuang G Zhao, Rohit Mehra, Andrew G Glass, Lucia LC Lam, Jijumon Chelliserry, Marguerite Du Plessis, Voleak Choeurng, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Jason Alter, Jennifer Jordan, Christine Buerki, Kasra Yousefi, Zaid Haddad, Elai Davicioni, Edouard J Trabulsi, Stacy Loeb, Ashutosh Tewari, Peter R Carroll, Sheila Weinmann, Edward M Schaeffer, Eric A Klein, R Jeffrey Karnes, Felix Y Feng, Paul L Nguyen
发表日期
2018/2/20
期刊
Journal of Clinical Oncology
卷号
36
期号
6
页码范围
581-590
出版商
American Society of Clinical Oncology
简介
Purpose
It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer.
Materials and Methods
Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups.
Results
With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National …
学术搜索中的文章
DE Spratt, J Zhang, M Santiago-Jiménez, RT Dess… - Journal of Clinical Oncology, 2018